{"name":"Invirsa, Inc.","slug":"invirsa-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"INV-102","genericName":"INV-102","slug":"inv-102","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"INV-102","genericName":"INV-102","slug":"inv-102","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNUzN1MEE0NTlVbzNzYkRsc2ZNVXFjX002SEpKcW91U3gzNGRrRVdyakd2bjBVbWlUSjVrTkZPekxuOERHeWt4dEwxNVR4YzZkamZiY21td2N3b2RNdWNNeVNNcjV3ZmliWlJ1ZmNwMTBudmktaUI0RkJzekpxa3QwY2t0all1Si1LZ2FNN21ZcTZuNFBwZWhfSld0cjA4MEVMdktmQ1FTM3ZrM2V5cFVMbDdwVTFQY01yWjZkX04yNnlRVTVxbXlKLTd3MHNXc2habEp0TTNYcXpuaG42SkJMcmVtaHNxUmt3RVdQbTZDNGQwUjR6LWVWN0NvbEpvenlkWk5ZWXp3?oc=5","date":"2026-03-12","type":"trial","source":"StreetInsider","summary":"Dry Eye Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight - StreetInsider","headline":"Dry Eye Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOZkpoOHZJTjRkbXVuWFhqZXVEMWM0b2pzaHQ3dTFZQWFQR3YxUVVzLU8ya2JEbEhKVjEtenMwb20xSDNfRE1tMTd0Qlg0bGROVmdyVURTQjM0STg3Q195aC1zVjJSbnFlR3FOd29PTm8ybGNGWGpkTFd0WERhek1scDEtc1JmUDdkVWxGendmd1Nnbklv?oc=5","date":"2026-03-12","type":"regulatory","source":"openPR.com","summary":"Diabetic Macular Edema Treatment Pipeline Shows Strong - openPR.com","headline":"Diabetic Macular Edema Treatment Pipeline Shows Strong","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOeVRIc3hVbmNpRG9aUUxiSV8tbDBUcjdzZHR6dnRBSGNkLUxuc21RcFloLTlzOUpZQ2RYbEdfZF9DQUNxSHZheExGQ2JRdzJ0ZmYtZG95SkxiUkFUMHFPUHdLQnR5R05sdHpRTmVZX2pzUFcyaC1MU0hXMldlMlEwRUFJVnd4RVM2RGdhREZSdDVCRUxzY1FB?oc=5","date":"2025-11-04","type":"trial","source":"bizjournals.com","summary":"Columbus biopharma company secures $18M for diabetic dry eye treatment trials - bizjournals.com","headline":"Columbus biopharma company secures $18M for diabetic dry eye treatment trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5QQ3JKVzhLckdRem9xbHVyaTlLamo3bVBhVUwxeWMzOVNFdERaV21LR1Y2Z0VBcnV3UWR0eElUNFZFV2lOTE9JVU5wUmJvUjJ3TXFEOGppMHJjWG9kSWJ6QVB2NW1hV0Frbk1EX0J3?oc=5","date":"2024-06-04","type":"pipeline","source":"Labiotech.eu","summary":"Ohio’s finest: Eight biotech companies leading the way - Labiotech.eu","headline":"Ohio’s finest: Eight biotech companies leading the way","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE1uOGJvaHRseUxXc3gtSlJJZ3VGSy12Nk50ZWZocGlCd05wYlB2Vy1jYjBZbUFKZkNRaGVCWnY2bHRPYkRxZVFhVGJnWVg5LXJmV2NZR1VnSmNEbWvSAWBBVV95cUxPSGtIbDVyNFRUUlpEWS0tenZSbXBZVGN1VW03b1dKNUV6ZU1OSS1yLWlENEQwclN4UzdCb2U2aFJ3NGhENmROSlNCbWZ0TG9LS0NaUEd5Rk5uaTU1cUxqenc?oc=5","date":"2023-07-03","type":"pipeline","source":"Pulse 2.0","summary":"Invirsa: Clinical-Stage Pharmaceutical Company Secures $7.7 Million - Pulse 2.0","headline":"Invirsa: Clinical-Stage Pharmaceutical Company Secures $7.7 Million - Pulse 2.0","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOSHJzZEJicHA3OFFsczd1enRobUpGa29HYW0xakhDTjd3WGtUa0FfVkR0Ql9LYzZHVGZrV2cxcFRHYWxnUlo0S3pqRUtpTzEyajZLRzlxMzhWNUVJT2M4cHItdDVGMUZsWEVtcURXajI5My1Ed2UyRnphSTJMVTdQWk5zVDZ1NHgzNy04TzFjZkJvLVZmT0NKalBadjJ6SlpJSEVr?oc=5","date":"2023-06-14","type":"pipeline","source":"Business Wire","summary":"Invirsa Completes $7.7M Series B Financing - Business Wire","headline":"Invirsa Completes $7.7M Series B Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOOVJIZ2V5ZFh5WHp6TzB2cF9vVnE2WUU3QzkzVVZkNEN2ME9QT0d2V3hpN0RLQTFhYjRaRVlsOXVHQzdDNklIVk1PcWZzVkEyMzFvTjNsUXA5bTB1NkJadjQ2NGlwSHZHQ0kyV3NuQjFuSk5WWWVVV09uYkJySTlTTEhJclRYbzJLNkhsRE9PLW1lZmdqc3hkbjg0d1Q2azhKakdvWGN2Q1Z5Zmh3MFhQSTdB?oc=5","date":"2023-05-16","type":"trial","source":"Eyes On Eyecare","summary":"Enrollment concludes for Invirsa's first-in-human DED study - Eyes On Eyecare","headline":"Enrollment concludes for Invirsa's first-in-human DED study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNSHFsUnRja05hcEF4YmVyOE5QZFByREZpTllIUW5VSW1ab2p3VVBzazZKSkN0MXppNEtROUJJNmdmaVpjazNoSHRvajdVcUhzY21nTEZ1VXRKelpvbGpibW5fMkw4QkJJSDJJb0hvWjNkc2d4NzdrQVQ5MWwwT0pwMWNjQk95ZEVBTmFZRXZ6ZzJEY016bHpSdC05UUpzaW9faXBYTU9pNXlMOFBnVjV2RHlUbVNkbFlmbkdwRlFsa01iVmtHQ1Vla1VhTUNoQ2VsVk1xdGNNa1RFNkhS?oc=5","date":"2020-11-05","type":"pipeline","source":"Homeland Preparedness News","summary":"BARDA puts up $30M for Invirsa effort to treat ocular conditions from sulfur mustard injuries - Homeland Preparedness News","headline":"BARDA puts up $30M for Invirsa effort to treat ocular conditions from sulfur mustard injuries","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}